GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (NAS:VYGR) » Definitions » Cyclically Adjusted PB Ratio

VYGR (Voyager Therapeutics) Cyclically Adjusted PB Ratio : 0.64 (As of May. 28, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-05-28), Voyager Therapeutics's current share price is $2.82. Voyager Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $4.43. Voyager Therapeutics's Cyclically Adjusted PB Ratio for today is 0.64.

The historical rank and industry rank for Voyager Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

VYGR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.65   Med: 1.54   Max: 2.39
Current: 0.65

During the past years, Voyager Therapeutics's highest Cyclically Adjusted PB Ratio was 2.39. The lowest was 0.65. And the median was 1.54.

VYGR's Cyclically Adjusted PB Ratio is ranked better than
66.52% of 669 companies
in the Biotechnology industry
Industry Median: 1.48 vs VYGR: 0.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Voyager Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $4.939. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.43 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Voyager Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Voyager Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Cyclically Adjusted PB Ratio Chart

Voyager Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.30

Voyager Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 1.93 1.40 1.30 0.76

Competitive Comparison of Voyager Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Voyager Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Voyager Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.82/4.43
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Voyager Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=4.939/134.9266*134.9266
=4.939

Current CPI (Mar. 2025) = 134.9266.

Voyager Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 4.071 100.684 5.456
201509 -1.833 100.392 -2.464
201512 6.782 99.792 9.170
201603 6.512 100.470 8.745
201606 6.160 101.688 8.174
201609 5.867 101.861 7.772
201612 5.310 101.863 7.034
201703 4.746 102.862 6.225
201706 4.049 103.349 5.286
201709 3.246 104.136 4.206
201712 4.246 104.011 5.508
201803 3.082 105.290 3.950
201806 2.557 106.317 3.245
201809 2.030 106.507 2.572
201812 1.435 105.998 1.827
201903 2.753 107.251 3.463
201906 3.228 108.070 4.030
201909 2.937 108.329 3.658
201912 2.699 108.420 3.359
202003 2.157 108.902 2.672
202006 2.067 108.767 2.564
202009 4.461 109.815 5.481
202012 4.130 109.897 5.071
202103 3.627 111.754 4.379
202106 2.926 114.631 3.444
202109 2.314 115.734 2.698
202112 2.507 117.630 2.876
202203 1.986 121.301 2.209
202206 1.562 125.017 1.686
202209 2.072 125.227 2.232
202212 1.528 125.222 1.646
202303 4.995 127.348 5.292
202306 4.548 128.729 4.767
202309 4.013 129.860 4.170
202312 5.366 129.419 5.594
202403 6.276 131.776 6.426
202406 6.158 132.554 6.268
202409 6.056 133.029 6.142
202412 5.477 133.157 5.550
202503 4.939 134.927 4.939

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Voyager Therapeutics  (NAS:VYGR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Voyager Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics Business Description

Traded in Other Exchanges
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Executives
Alfred Sandrock director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Todd Alfred Carter officer: Chief Scientific Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
Robin Swartz officer: Chief Operating Officer C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Sandell Jacquelyn Fahey officer: Chief Legal Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
Peter P. Pfreundschuh officer: Chief Financial Officer C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Robert W. Hesslein officer: Senior VP & General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Jude Onyia director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Neurocrine Biosciences Inc 10 percent owner 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael J Higgins director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Glenn Pierce director